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Activation of b-catenin and Akt pathways by
Twist are critical for the maintenance of EMT
associated cancer stem cell-like characters
Junlin Li1,2, Binhua P Zhou1,2*
Abstract
Background: Epithelial-mesenchymal transition (EMT) not only confers tumor cells with a distinct advantage for
metastatic dissemination, but also it provides those cells with cancer stem cell-like characters for proliferation and
drug resistance. However, the molecular mechanism for maintenance of these stem cell-like traits remains unclear.
Methods: In this study, we induced EMT in breast cancer MCF7 and cervical cancer Hela cells with expression of
Twist, a key transcriptional factor of EMT. The morphological changes associated with EMT were analyzed by
immunofluorescent staining and Western blotting. The stem cell-like traits associated with EMT were determined
by tumorsphere-formation and expression of ALDH1 and CD44 in these cells. The activation of b-catenin and Akt
pathways was examined by Western blotting and luciferase assays.
Results: We found that expression of Twist induced a morphological change associated with EMT. We also found
that the cancer stem cell-like traits, such as tumorsphere formation, expression of ALDH1 and CD44, were
significantly elevated in Twist-overexpressing cells. Interestingly, we showed that b-catenin and Akt pathways were
activated in these Twist-overexpressing cells. Activation of b-catenin correlated with the expression of CD44.
Knockdown of b-catenin expression and inhibition of the Akt pathway greatly suppressed the expression of CD44.
Conclusions: Our results indicate that activation of b-catenin and Akt pathways are required for the sustention of
EMT-associated stem cell-like traits.
Background
Tumor recurrence is one of the biggest challenges in
breast cancer, because it often leads to an incurable dis-
ease. Therapeutic resistance, the major mechanism
underlying tumor recurrence, raises the question of
whether conventional anticancer therapies target the cor-
rect cells. The existence of a subpopulation of tumor
cells with stem cell-like characteristics, such as very slow
replication and resistance to standard chemotherapy,
poses a new concept to account for the phenomena of
drug resistance and tumor recurrence. It was not until
1994 that cancer stem cells (CSCs, also known as tumor-
initiating cells) were first identified in human acute mye-
loid leukemia malignancies [1]. Subsequent studies have
identified CSCs in solid tumors, including breast [2],
prostate [3,4], brain [5], colon [6], and pancreas [7,8]. For
example, breast cancer stem cells are characterized by
low levels of heat stable antigen (CD24) and high levels
of hyaluronan receptor (CD44) expression. This subpo-
pulation of cells has the ability to self-renew, and to initi-
ate tumor formation, and is intrinsically resistant to
therapy. The cancer stem cell hypothesis has fundamen-
tal clinical implications, as current treatment strategies
may affect the bulk of the tumor cells but leave CSCs
behind, serving as a reservoir for disease recurrence and
metastasis [9-11]. Therefore, the elucidation of molecular
pathways, which regulate self-renewal activity of CSCs
and their interaction with niche, will provide potential
therapeutic targets.
Although the CSCs hypothesis suggests that tumors
can arise from stem or progenitor cells, studies from
many laboratories indicate that epithelial-mesenchymal
transition (EMT) can endow cells with stem-cell
like characteristics [12-15]. EMT is an embryonic
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developmental process in which epithelial cells lose
expression of many markers of differentiation, acquire
fibroblast-like properties and show reduced intercellular
adhesion and increased motility [16-18]. EMT has been
recognized not only as a physiological mechanism for
development and tissue remodeling, but also as a patho-
logical mechanism in the progression of various diseases
including inflammation, fibrosis and cancer [16,17].
Weinberg and his colleagues showed that induction of
EMT in immortalized human mammary epithelial cells
results in an increased ability to form tumorspheres, and
in the expression of stem cell-like markers [13]. Specifi-
cally, cells with CD44+CD24low phenotype, which
yielded tumor formation with as few as 100 cells (com-
pared with that the control), were found significant
increased when cells were treated with transforming
growth factor-beta or were overexpressing the key EMT
inducers, Snail and Twist. These data indicate that
EMT endows tumor cells with stem cell-like properties.
Consistent with this finding, tumor cells resistant to
chemo- and endocrine therapies activate the EMT pro-
gram, which results in the expansion of CSCs with
CD44+CD24low expression [13,14,19]. However, it is
unclear how the activation of the EMT program contri-
butes to the expansion of CSCs with CD44+CD24low
traits.
A hallmark of EMT is the loss of E-cadherin expression
[16-18]. E-cadherin is a cell-cell adhesion molecule that
participates in homotypic, calcium-dependent interac-
tions to form epithelial adherent junctions [20,21]. Loss
of E-cadherin expression is often correlated with the
tumor grade and stage [20,21], because it results in the
disruption of cell-cell adhesion and an increase in nuclear
b-catenin, thus leading to cell growth and survival. On
one hand, b-catenin is an essential component of adher-
ent junctions, where it provides the link between E-cad-
herin and b-catenin and modulates cell-cell adhesion and
cell migration [22]. On the other hand, b-catenin also
functions as a transcription cofactor with T cell factor
(TCF). In unstimulated cells, the level of free cytoplasmic
b-catenin is kept low through a destruction complex,
which consists of axin, adenomatous polyposis coli
(APC), GSK-3b and casein kinase (CKI). GSK-3b phos-
phorylates b-catenin and triggers its ubiquitination and
degradation by b-Trcp. In the presence of Wnt ligands,
Wnts bind to frizzled and LRP5/6 receptor complex to
inactivate GSK-3b in the destruction complex. This, in
turn, results in the stabilization and nuclear accumula-
tion of b-catenin and leads to the activation of the Wnt/
b-catenin signaling pathway [22], which has been impli-
cated in stem cell maintenance and self-renewal.
In this study, we found that the expression of Twist
induced EMT and the expansion of the CD44high-
CD24low subpopulation, which is associated with CSC
properties. We showed that b-catenin and Akt pathways
were activated in these Twist-overexpressing transfec-
tants. The nuclear accumulation of b-catenin correlated
with the expression of CD44. Knockdown of b-catenin
expression and inhibition of the Akt pathway signifi-
cantly decreased the expression of CD44. Together, our
results indicate that the activation of b-catenin and the
Akt pathway is required for the sustention of cancer
stem cell-like traits generated by EMT.
Methods
Cell cultures, transfections and reporter assays
MCF7 and Hela cells were cultured with DMEM med-
ium supplemented with 10% fetal bovine serum in a
humidified CO2 incubator at 37°C. To generate Twist-
expression stable transfectants, Hela and MCF7 cells
were transfected with pcDNA3-Twist1, and stable clones
were selected with 1000 μg/ml of G418 (CALBIO-
CHEM) for 4 weeks.
TOPflash or FOPflash plasmid (Upstate, Lake Placid,
NY) was transiently transfected into cells with Fugene 6
(Roche, Indianapolis, IN). For measuring the transcrip-
tion of CD44, pGL3-CD44P was also expressed in cells.
To normalize transfection efficiency, cells were also co-
transfected with 0.1 μg of the pRL-CMV (Renilla lucifer-
ase). Forty-eight hours after transfection, luciferase
activity was measured using the Dual-Luciferase Assay
kit (Promega, Madison, WI). Three independent experi-
ments were performed, and the calculated means and
standard deviations are presented.
To knock down the expression of b-catenin, cells were
seeded on 6-well plates and transfected with pGL3-
CD44P, along with validated human b-catenin siRNA
(Dharmacon) at a final concentration of 100 nM using
X-tremeGENE siRNA transfection reagent (Roche) fol-
lowing manufacturer’s instructions. After 36 h of trans-
fection, cells were treated with or without PI3K/Akt
inhibitors wortmannin (100 nM) for overnight. Lucifer-
ase activity was measured as described above. All experi-
ments were performed at least three times in triplicate.
Commercial antibodies used in this study were pre-
sented in Table 1.
Western Blot Analysis
To prepare the whole-cell extract, cells were washed
with PBS once and harvested by scraping them in 1 ml
lyses buffer (50 mM Tris-HCl pH7.4, 150 mM NaCl,
0.2 mM EDTA, 0.2% NP-40, 10% Glycerin, 1M b-Me,
1 μg/ml Aprotin, 0.5 μg/ml Leupetin, 0.1 mM Na3VO4,
0.5 mM 4NPP, 0.5 mM NaF, and protease inhibitors).
Cellular lysates were centrifuged at 13,200 × g for 5 min
at 4°C. Protein content was determined by the Bradford
assay (Bio-Rad Laboratories, Hercules, CA). The
extracted proteins were separated in a 10-12%
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SDS-polyacrylamide gel electrophoresis and transferred
to a nitrocellulose membrane (Amersham Bioscience).
The membranes were first blocked with 5% (w/v) nonfat
dry milk in PBST and then probed with the indicated
primary antibodies with gentle shaking at 4°C overnight.
After washing the membranes four times, the mem-
branes were incubated with the appropriate peroxidase-
conjugated secondary antibodies for 1 hour. The signals
were detected using an enhanced chemiluminescence kit
(Amersham Biosciences).
Immunofluorescent Analysis
Cells were grown on glass chamber slides fixed with 4%
paraformaldehyde in PBS for 30 min. Then cells were
permeabilized in 0.1% Triton X-100 for 30 min and
blocked with 0.5% bovine serum albumin in PBS for
30 min at room temperature. After washing with PBS,
the cells were incubated with specific primary antibodies
for 1 hour at room temperature. After being washed
with PBST, the cells were incubated with appropriate
fluorescein isothiocyanate-conjugated secondary antibo-
dies and then stained with 4’, 6-diamidino-2-phenylin-
dole (DAPI) (Roche Diagnostics). The images were
visualized with an Olympus microscope.
Flow Cytometry Analysis
Flow Cytometry Analysis was performed as described
previously [23]. Cells were harvested by trypsinization
and washed twice with PBS. The cells then were fixed
and stained with monoclonal antibodies against
CD44, CD24 or an isotype IgG, labeled with Alexa 488-
conjugated secondary antibody, and subjected to flow
cytometric analysis using a flow cytometer (BD-LSR
model, Becton-Dickinson, San Jose, CA).
Tumorsphere Culture
Single-cell suspensions were suspended at a density of
4,000 cells per milliliter in Dulbecco’s modified Eagle’s
medium/F-12 (Twist/MCF7, MCF7) or Dulbecco’s mod-
ified Eagle’s medium (Twist/HeLa; HeLa) and seeded
into six-well plates (2.0 mL per plate) coated with 1.2%
poly-Hema. Suspension cultures were continued for
1-2 weeks (7-day for Hela and Twist/Hela cells; 12-day
for MCF7 and Twist/MCF7 cells) until the formation of
tumorspheres. Colonies were counted at 10 different
views under microscope. Experiments were repeated
three times with duplication in each experiment.
Cellular Fractionation Analysis
Cellular fractionation was performed as described by
Abmayr et al with minor modifications [24]. Briefly,
cells were harvested with trypsinization and washed
twice with phosphate-buffered saline (137 mM NaC1,
2.7 mM KC1, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH
7.4). Cells were rapidly washed once with hypotonic buf-
fer (10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM
KCl, 0.2 mM PMSF, and 0.5 mM DTT), re-suspended
with 3 packed cell volume of hypotonic buffer and
allowed to swell on ice for 10 min. Cells were then
homogenized with 20 strokes on Dounce homogenizer
(type B pestle) to ensure that >95% of cells were lyzed.
After centrifugation at 4°C with 3300 × g for 15 min,
Supernatant was saved for S-100 cytoplasmic extract
preparation. The nuclear pellet was washed once with
lysis buffer (50 mM Tris-HCl pH7.4, 150 mM NaCl,
0.2 mM EDTA, 0.2% NP-40, 10% Glycerin, and protease
cocktail) and suspected in the same buffer. After brief
sonication, the suspension was spin at 13,200 × g for
20 min and supernatant was saved as the nuclear frac-
tion. To prepare the membrane and cytoplasmic frac-
tions, the supernatant saved above was centrifuged at
100,000 × g for 20 minutes at 4°C, Supernatant was
saved as the cytoplasmic fraction. The pellet was re-sus-
pended in lysis buffer containing 1% of Trition X-100
and save as the membrane fraction.
Equal proteins from these three fractions for parental
and Twist-overexpressing cells were used for western
blotting analysis.
Preparation of Wnt3a Conditioned-Medium
Wnt3A-conditioned media was prepared as described by
Willert et al [25]. Briefly, stable murine L-cells (ATCC,
Manassas, VA) that overexpress Wnt3A were main-
tained in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum, 1% L-glutamine,
Table 1 Antibodies used in this study
Name Antigen Source Manufacturer
Twist Twist Rabbit Cell signaling
Snail Snail Rat Cell signaling
N-cadherin N-cadherin Mouse Upstate
Fibronectin Ab-11 Fibronectin Mouse Neo Markers
Vimentin Ab-2 Vimentin Mouse Neo Markers
g-catenin g-catenin Mouse BD
transduction
E-cadherin E-cadherin Mouse BD
transduction
ZO-1 ZO-1 Rabbit Abcam
p-GSK-3b (Ser9) GSK-3b (Ser9) Mouse Upstate
GSK-3b GSK-3b Goat Santa Cruz
p-Akt (Ser473) Akt (Ser473) Rabbit Cell signaling
Akt Akt1,2,3 Rabbit Cell signaling
p-b-catenin(Ser33/37/
Thr41)
b-catenin (Ser33/37/
Thr41)
Rabbit Cell signaling
b-catenin b-catenin Rabbit Abcam
b-tubulin b-tubulin Mouse Sigma
Anti-FLAG M2 FLAG-tag Mouse Sigma
CD44 CD44 Mouse Cell signaling
PE-Cy7-CD44 CD44 Rat eBioscience
PE-CD24 CD24 Mouse eBioscience
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and 0.4 mg/ml Geneticin. To obtain Wnt3A-conditioned
media, cells were seeded into 100-mm dishes and cul-
tured for 4 days in growth medium without G418, the
medium was removed and sterile-filtered. Fresh medium
was added to the plates and cultured for an additional 3
days. The medium was then removed, sterile-filtered
and combined with the initial batch of cultured media,
and stored at -80°C in aliquots as Wnt3A conditioned
medium.
Statistical Analysis
The experiments were repeated at least two times.
Results are expressed as mean ± SD or SEM as indi-
cated. An independent Student’s t-test was performed to
analyze the luciferase assay and other analyses. p < 0.05
was considered statistically significant.
Results
Expression of Twist induces EMT in Hela and MCF7 cells
To examine the role of Twist in EMT induction and the
generation of stem-cell like properties, we generated
Twist-stable expression clones in cervical cancer Hela
and breast cancer MCF7 cells. Expression of Twist
induced EMT in these cells as morphological changes
from a cobble-stone-like shape to a spindle-like appear-
ance were noted; these cells became elongated in shape
and disassociated from their neighboring cells (Figure 1a).
Immunofluoresent staining showed the upregulation of
mesenchymal markers N-cadherin and vimentin and the
downregulation of epithelial markers ZO-1 (Figure 1a).
Interestingly, b-catenin was accumulated and translocated
into both the cytoplasm and the nucleus. Similar results
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Figure 1 Overexpression of Twist induces EMT in Hela and MCF7 cells. (a) Hela and MCF7 cells and their corresponding Twist-
overexpressing stable transfectants were analyzed for the expression of N-cadherin, Vimentin, ZO-1, and b-catenin by immunofluorescent
staining. Nuclei were visualized with DAPI staining (blue). Cell morphological changes associated with EMT are shown in the phase contrast
images. (b) Expression of E-cadherin, Twist, N-cadherin and vimentin in these cells was analyzed by Western blotting. b-tubulin served as a
loading control.
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were further confirmed by Western blotting using specific
antibodies against E-cadherin, ZO-1, N-cadherin and
vimentin (Figure 1b). Consistent with these molecular
changes, cell motility was significantly enhanced in cells
expressing Twist than that of parental cells (Figure 2a).
These results indicate that expression of Twist can
induce EMT in Hela and MCF7 cells, which is accompa-
nied with the downregulation of epithelial markers and
upregulation of mesenchymal molecules, and thus, results
in the enhancement of cell motility.
Expression of Twist induces stem-cell like properties in
Hela and MCF7 cells
The tumorsphere assay, based on the unique property of
stem/progenitor cells to survive and grow in serum-free
suspension, was successfully used to establish long-term
cultures enriched in stem/progenitor cells from invasive
tumor samples. To examine whether the expression of
Twist induced stem cell-like properties in Hela and
MCF7 cells, we performed a tumorsphere formation
assay. Surprisingly, the expression of Twist induced
about a 24- and 18-fold enhancement in tumorsphere-
formation in Hela and MCF7 cells, respectively, com-
pared with that of parental cells (Figure 2b). To further
confirm these findings, we also measured the level of
aldehyde dehydrogenase 1 (ALDH1), a detoxifying
enzyme responsible for the oxidation of retinol to reti-
noic acid and which has a role in the early differentia-
tion of stem cells. High ALDH1 activity is associated
with several types of murine and human hematopoietic
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Figure 2 Twist enhances migration, tumorsphere-formation and ALDH1 activity. (a) Hela and MCF7 cells and their corresponding
transfectants were seeded on 6-well plates. After 48 h, a scratch ("wound”) was induced in a cell monolayer, and cell culture was continued for an
additional 24 h. Images were obtained at the beginning and at the 24 h time point to monitor the cell migration for the closure of the wound. The
percentage of cell migration was calculated based on the migration of Hela and MCF7 cells (mean ± SEM in three separate experiments) and the
representative images were shown in the left panel. *P < 0.01 for Hela cells compared with the corresponding Twist-overexpressing cells. #P < 0.05
for MCF7 cells compared with the corresponding Twist-overexpressing transfectants. (b) The tumorsphere formation was measured in Hela and
MCF7 cells and in their corresponding Twist-overexpressing stable transfectants as described in Materials and Methods. The statistical analysis for
the tumorsphere formation from three independent experiments in duplicate was calculated and presented. * and # P < 0.01 for Hela and MCF7
cells compared with their corresponding Twist-overexpressing transfectants. (c) The expression of ALDH1 in Hela and MCF7 cells and their
corresponding Twist-overexpressing stable transfectants were analyzed by Western blotting. b-tubulin served as a loading control.
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and neural stem/progenitor cells. As shown in Figure 2c,
the expression of Twist significantly induced the level of
ALDH1 in Hela and MCF7 cells.
The CD44high/CD24low phenotype has been used to
isolate stem cells from the human normal mammary
epithelium [2]. It has been shown that as few as 200 of
these cells generated tumors in NOD/SCID mice
whereas 20,000 cells that did not display this phenotype
failed to do so. These cells were able to self-renew, dif-
ferentiate, and display CSC features. To examine
whether expression of Twist induces the expansion of
this population of cells, we measured the expression of
CD44 by Western blotting, immune-fluorescence stain-
ing and FACS analyses. As shown in Figures 3a, b and
3c, expression of Twist dramatically elevated the level of
CD44 in Hela and MCF7 cells. Consistent with these
observations, when CD44 promoter luciferase plasmid
was expressed in these cells, the luciferase activity was
significantly elevated in Twist-overexpressing cells than
that of parental cells (Figure 3d). Together, these results
indicate that the expression of Twist is critical in EMT
induction, which confers cells with stem-cell like prop-
erties by inducing the expression of CD44 and enhan-
cing tumorsphere formation and ALDH1 activity.
Expression of Twist induces the activation of b-catenin
signaling pathway
b-catenin plays an important role in a variety of human
tumors. Downregulation of E-cadherin expression often
results in an increase of b-catenin, which binds to TCF/
LEF to participate in transcription regulation. To test
whether the b-catenin pathway was activated in cells
expressing Twist, we isolated b-catenin from the mem-
brane, the cytoplasm and the nucleus of parental and
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Figure 3 Twist induces the expression of CD44. (a-c) The expression of CD44 in Hela and MCF7 cells and their corresponding Twist-
overexpressing stable transfectants were analyzed by Western blotting (a), immunofluorescent staining (b), and FACS (c). (d) CD44 promoter
luciferase plasmid was expressed in Hela and MCF7 cells and their corresponding Twist-overexpressing stable transfectants. After 48 hr, luciferase
activity was measured by using a Dual-Luciferase Reporter Assay (Promega) (mean ± SD of three separate experiments). * and # P < 0.05 for Hela
and MCF7 cells compared with their corresponding Twist-overexpressing cells.
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Twist-overexpressing cells. Although the membrane-
bound b-catenin was significantly decreased, the total
level of b-catenin, the cytoplasmic and the nuclear b-
catenin were greatly increased in cells expressing Twist
(Figure 4a). b-catenin is a labile protein, and it subjected
to GSK-3b-mediated phosphorylation and proteasome
degradation. Interestingly, we found that the phosphory-
lation of b-catenin was significantly reduced in cells
expressing Twist, suggesting that the increase of the
cytoplasmic and the nuclear b-catenin from Twist-over-
expressing cells resulted from the release of membrane-
fraction b-catenin as well as from the inhibition of phos-
phorylation and degradation of b-catenin in these cells.
To further confirm the activation of the b-catenin path-
way, we measured the TOP/FOP luciferase activities.
Both Twist-overexpressing cell lines have higher lucifer-
ase activities than that of the corresponding parental
cells (Figure 4b). Taken together, these data showed that
EMT induces an accumulation and nuclear translocation
of b-catenin and thus activates the Wnt/b-catenin sig-
naling pathway.
We also treated Hela cells with Wnt3a, a ligand
known to activate the Wnt/b-catenin pathway. As
expected, Wnt3a induced b-catenin stabilization in Hela
cells (Figure 5a) and a corresponding upregulation of
TOP/FOP luciferase activity (Figure 5b). Although
Twist-overexpressing Hela cells contained higher levels
of b-catenin, and treatment with Wnt3a did not further
elevate the level of b-catenin (Figure 5a), Wnt3a can
further enhance the TOP/FOP luciferase by more than
10-fold (Figure 5c); this suggests that EMT can syner-
gize the activation of b-catenin induced by Wnt ligands.
CD44 expression was part of a genetic program con-
trolled by the b-catenin/Tcf-4 signaling pathway [26].
Over-expression of the CD44 family is an early event in
the colorectal adenoma-carcinoma process, which sug-
gests b-catenin/Tcf-4 signaling is crucial in initiating
tumorigenesis [27]. Masaki et al supported this result
with the immunostaining of b-catenin and CD44, sug-
gesting that the up-regulation of CD44 through nuclear
b-catenin contributed to the formation of the tumor
[28]. Thus, we measured the CD44 luciferase in Twist-
overexpressing cells stimulated with Wnt3a. We found
that CD44 luciferase levels were further elevated by
Wnt3a (Figure 5c), indicating that the activation of the
b-catenin pathway plays a critical role in the expansion
of CD44+ cells with stem-cell like properties.
Expression of Twist activates Akt signaling pathway and
increases the level of Snail
Twist has been shown to activate the Akt signaling path-
way by inducing the expression of Akt [29]. To examine
whether the expression of Twist activates the Akt signal-
ing, we measured the phosphorylation of Akt in cells
Figure 4 Twist activates b-catenin pathway. (a) The expression of total, membrane, cytosol, nuclear and phosphorylated forms of b-catenin
were examined by Western blotting. b-tubulin served as a loading control. (b) The activation of b-catenin was examined by measuring the
transcription activity of Top/Fop luciferase in Hela and MCF cells and their corresponding stable transfectants (mean ± SD of three separate
experiments). * and # P < 0.05 for Hela and MCF7 cells compared with their corresponding Twist-overexpressing cells.
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expressing Twist and their corresponding parental cells.
We found that Akt was activated in Hela and MCF7 cells
expressing Twist (Figure 6a). Serine/threonine protein
kinase GSK-3b, a downstream target of PI3K/Akt, was
also found to be inactivated by phosphorylation at serine
9, whereas the total GSK-3b level remained changed. As
GSK-3b can phosphorylate b-catenin and result in its
proteasome degradation, this result was consistent with
our finding that b-catenin was stabilized because of the
significantly reduced level of phosphorylation (Figure 4a).
Figure 5 Wnt3a can further enhance the activation of b-catenin in Twist-overexpressing cells. (a) Expression of b-catenin before or after
Wnt3a stimulation (Wnt3a conditioned medium for overnight) was measured by Western blotting. b-tubulin served as a loading control. (b) The
activation of b-catenin before and after Wnt3a stimulation (Wnt3a-conditioned medium for overnight) was examined by measuring the
transcription activity of Top/Fop luciferase in Hela cells and their corresponding stable transfectants (mean ± SD of three separate experiments).
*P < 0.05 for Hela cells compared with the corresponding Twist-overexpressing cells. #P < 0.01 for Twist/Hela cells compared with cells treated
with Wnt3a. Non-significant (ns) was found between Hela cells treat with and without Wnt3a. (c) CD44 promoter luciferase plasmid was
expressed in Hela cells and their corresponding Twist-overexpressing stable transfectants. After 36 hr, cells were treated overnight with a Wnt3a-
conditioned medium and luciferase activity was measured by using a Dual-Luciferase Reporter Assay (Promega) (mean ± SD of three separate
experiments). * and # P < 0.05. Non-significant (ns) was found between Hela cells treat with and without Wnt3a.
Figure 6 Twist induces the activation of Akt and the protein stabilization of Snail. (a) The activation of Akt (phosphorylated Akt) and the
suppression of GSK-3b (phosphorylated GSK-3b) were examined by Western blotting in Hela and MCF cells and their corresponding stable
transfectants. (b) The level of Snail in Hela and MCF cells and their corresponding stable transfectants was examined by Western blotting.
b-tubulin served as a loading control.
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The activation of Akt and suppression of GSK-3b in
Twist-expressing cells were quite interesting, as we
showed previously that GSK-3b is the major kinase regu-
lating the protein stability and the cellular localization of
Snail [30]. To further extend this finding, we examined
the expression of Snail in these cells. We found that the
level of Snail was significantly higher in Twist-overex-
pressing cells than that of parental cells (Figure 6b).
Together, our results indicate that expression of Twist
can induce the activation of Akt and the suppression of
GSK-3b, which results in the stabilization of b-catenin
and Snail in Hela and MCF7 cells.
Inhibition of b-catenin and Akt signaling pathways
suppress CD44 expression
We showed that EMT induced the downregulation of
E-cadherin and the detachment of b-catenin from mem-
brane localization. We further showed that EMT acti-
vated Akt and suppressed the function of GSK-3b,
which is required for the stabilization and nuclear trans-
location of b-catenin, and thus results in the transcrip-
tion of CD44. To investigate whether the b-catenin and
Akt pathways were critical for the induction of CD44,
we knocked down the expression of b-catenin or inhib-
ited the Akt pathway by wortmannin in cells. We found
that either the knockdown of b-catenin expression or
the inhibition of Akt pathway suppressed the expression
of CD44 (Figure 7a). Inhibition of both pathways can
further synergistically suppress the expression of CD44,
suggesting that the activation of these two pathways is
critical for the maintenance of CD44 expression.
Discussion
In this study, we showed that the expression of Twist
induced EMT in Hela and MCF7 cells, and that accompa-
nied the increased stem cell-like properties and the upre-
gulation of CD44. We found that the upregulation of
CD44 was mediated by the activation of b-catenin and
Akt pathways in these cells; inhibition of both pathways
synergistically suppressed the upregulation of CD44. Our
study provides several new insights into the regulation of
EMT and cell differentiation program. First, our results
indicate that the activation of b-catenin and Akt pathways
is critical for the maintenance of the stem cell-like proper-
ties associated with EMT (Figure 7b). The gain-of-function
of stem cell-like properties in EMT may confer tumor cells
the survivability against chemo- and endocrine therapies,
in addition to a distinct advantage for invasion and metas-
tasis [13,14,19]. However, the molecular link between
EMT and the gain of CSCs properties is unclear; whether
Figure 7 Blockage of b-catenin and Akt pathways suppresses CD44 expression. (a) The expression of b-catenin was knocked down or cells
were treated with wortmannin as described in the Materials and Methods. The luciferase activity of CD44 was measured by using a Dual-
Luciferase Reporter Assay (Promega) (mean ± SD of three separate experiments). (b) A proposed model to illustrate how Twist activates
b-catenin and Akt pathways to maintain the expression of CD44 and stem cell-like properties associated with EMT.
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a shared signaling pathway regulates both processes
remains to be determined. The Wnt/b-catenin pathway
mediates a wide variety of processes, including cell prolif-
eration, migration, differentiation, adhesion and apoptosis.
It is critical for homeostatic stem cell renewal. For exam-
ple, Wnt signaling is necessary for maintenance of stem
cells in the intestinal crypts [31]. Treating prostate cancer
cells with stem cell-like characteristics with WNT inhibi-
tors reduced both the size of tumorspheres and the ability
of self-renewal, whereas Wnt3a stimulates them [32]. Con-
sistent with previous reports [12-15], we found that over-
expression of Twist induced EMT in Hela and MCF7
cells, which accompanied the gain-of-function of stem
cell-like properties, such as high levels of ALDH1 expres-
sion, tumorsphere-formation and high levels of CD44. We
further showed that the b-catenin pathway was activated
as the membrane-bound and phosphorylated b-catenin
was significantly decreased in Twist-overexpressing Hela
and MCF7 cells. E-cadherin is known to anchor and to
sequester b-catenin in the membrane and prevent it from
activation; the activation of b-catenin signaling may result
from the downregulation of E-cadherin at EMT. CD44 has
been shown to be a downstream target of the b-catenin
signaling pathway. We found that elevated CD44 corre-
lated with the activation of b-catenin in Twist-overexpres-
sing cells. Interestingly, the activation of the b-catenin
pathway was not optimal, as treatment of Wnt3a
can further induce the activation of b-catenin and the
induction of CD44, suggesting that EMT initiates and
primes b-catenin activation and this activation can be
further synergized by the Wnt ligand from the tumor
microenvironment.
The expression of Twist also has been shown to activate
the Akt pathway to promote migration, invasion and pacli-
taxel resistance [29]. The activation of Akt phosphorylated
and suppressed GSK-3b, which is the major kinase for the
phosphorylation of b-catenin and Snail [30,33]. The phos-
phorylation of these molecules by GSK-3b results in the
consequent degradation of b-catenin and Snail by E3 ligase
b-Trcp [30,33]. Consistent with these findings, we discov-
ered that Akt was activated in Twist-overexpressing cells,
which lead to the phosphorylation and suppression of
GSK-3b and resulted in the significant protein stabilization
of b-catenin and Snail in these cells. When E-cadherin is
downregulated at EMT, the released cytoplasmic b-catenin
is still subjected to GSK-3b mediated phosphorylaton and
degradation. Thus, additional activation of the Akt path-
way is necessary to prevent this process and facilitates the
nuclear translocation and activation of b-catenin. This
speculation is consistent with the fact that EMT also cor-
relates with the presence of b-catenin in the nucleus [34].
Thus, activation of b-catenin and Akt pathways is a syner-
gistic event at EMT and is critical for generating high-
grade invasive cells with stem cell-like features (Figure 7b).
Second, our results suggest that targeting the b-cate-
nin and Akt pathways can suppress the stem cell-like
properties associated with EMT. CSCs are often
resistant to common drugs in vivo and in vitro when
compared with the majority of the cancer cell popula-
tion, raising the question of whether traditional ther-
apy only “debulks” tumors, leaving CSCs to repopulate
the original tumor and which results in disease recur-
rence. Consistent with these findings, Cheng and her
colleagues showed that the residual breast tumor cell
populations that survived after conventional treatment
were enriched for the subpopulation of cells with both
tumor stem cell-like features and EMT characteristics
[9,11]. Thus, more effective therapies will require the
selective targeting of this crucial cell population. The
elucidation of molecular pathways underlying the regu-
lation of CSC self-renewal and survival is crucial to the
success of this goal. In our study, we found that either
the knockdown of b-catenin expression or the suppres-
sion of the Akt pathway by wortmannin inhibited
CD44 expression. Moreover, the combination of both
chemical suppression and siRNA knockdown signifi-
cantly suppressed the expression of CD44, indicating
the synergistic effect of these two pathways in main-
taining the stem cell-like properties associated with
EMT. Gupta et al. recently implemented a chemical
screen and discovered compounds showing selective
toxicity for breast CSCs, including salinomycin [35]. It
would be interesting to test whether Salinomycin inhi-
bits the activation of b-catenin and Akt pathways in
the near future.
Conclusion
In summary, we showed that the activation of b-catenin
and Akt is critical for the maintenance of CD44 expres-
sion associated with EMT. Targeting these pathways, in
conjunction with currently used conventional treat-
ments, may provide a new therapeutic strategy for elimi-
nating surviving tumor cells to prevent recurrence and
to improve long-term survival in cancer patients.
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